key: cord-0828647-j8h7iz6e authors: Zhou, Hong-Yan; Yang, Nan; Sui, Hua; Du, Xiang-Ning; Luo, Qi; Zhao, Yang-Jianing; Zhou, Yang-Wanxia; Guan, Qing; Zhou, Yue; Qian, Hong-Jie; Liu, Lu; Wang, Da-Peng; Lin, Hong-Li title: The Role of the Vascular Niche in Organ Fibrosis and COVID-19-Related Organ Damage and the Countermeasures adopted by Chinese and Western Medicine date: 2022-03-29 journal: Pharmacological Research - Modern Chinese Medicine DOI: 10.1016/j.prmcm.2022.100085 sha: e9442bc0038f13f8c5b533f96d966f28dcc9200e doc_id: 828647 cord_uid: j8h7iz6e The vascular niche is a microenvironment located around capillaries and is mainly composed of endothelial cells, pericytes, macrophages, lymphocytes, mesenchymal stem cells, and hematopoietic stem cells. Studies have found that the vascular niche not only functions to regulate cell growth and differentiation in normal tissues, but also has an important role in regulating fibrosis in various organs and tissues in disease states. Coronavirus disease 2019 (COVID-19) is a systemic disease that broke out in 2019, caused by SARS-CoV-2 infection, which results in pulmonary inflammation, systemic multi-organ damage, and an inflammatory cytokine storm. Recently, the vascular niche has been found to play a role in COVID-19-related multi-organ damage. In this review, we introduce the important role of the vascular niche in organ fibrosis and COVID-19-related organ damage, summarize some of the cellular signaling pathways in the vascular niche that promote fibrosis, and discuss the treatment of organ fibrosis in Traditional Chinese medicine and Western medicine. tissue growth promoting factors (vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF)), which contribute together to the development and progression of organ fibrosis [9, [14] [15] [16] (Figure 1) . In a series of experiments by Ding et al., it was also demonstrated that the vascular secretory function of the vascular niche has an important role in alveolar regeneration and liver damage repair, suggesting the feasibility of modulating the vascular niche as a new approach to treat pulmonary fibrosis [17, 18] . In addition to vascular secretory effects, the vascular niche also Many studies have showed that ECs, pericytes, and macrophages of the vascular niche in different organs can be aberrantly activated and transformed into myofibroblasts in response to chronic injury and inflammatory stimuli, via processes known as endothelial to mesenchymal transition (EndoMT), pericyte to myofibroblast transition (PMT), and macrophage to 5 myofibroblast transition (MMT) [19] [20] [21] . These cellular transformations not only lead to an increase in fibroblasts in the tissue interstitium, but also cause an increase in capillary permeability, which exacerbates inflammatory cell infiltration and tissue hypoxia, and further aggravates organ damage [22] . Thus, the role of the vascular niche in the process of organ fibrosis cannot be ignored. COVID-19 is a pulmonary disease; however, another significant clinical manifestation of COVID-19 is virus-induced impairment of multiple organ functions. During the investigation and treatment of SARS-CoV-2 infections, researchers have found that most infected patients present with multiple organ involvement, such as pulmonary fibrosis, myocarditis, renal interstitial fibrosis, cholangitis, gastroenteritis, and rash, as well as the deposition of viral particles in damaged cells, which occurs by a mechanism closely related to direct viral infection of cells expressing high levels of angiotensin-converting enzyme 2 (ACE2) [23] [24] [25] [26] [27] [28] (Figure 2 ). The lung is the most severely affected organ by COVID-19, and Yu et al. found that some patients showed fibrotic characteristics, such as parenchymal bands, irregular interfaces, and interstitial thickening on lung computed tomography (CT) during the follow-up of patients cured of pneumonia [29] . In addition to direct infection of epithelial cells with SARS-CoV-2 causing diffuse alveolar epithelial destruction, pathological autopsy findings of patients who died from COVID-19 also showed the presence of alveolar capillary damage, hemorrhage, endothelial cell necrosis, and inflammatory cell infiltration, indicating that the vascular niche was severely damaged during the infection [30] . Conde et al. found that human primary ECs that do not express ACE2 were not infected with SARS-CoV-2, whereas ACE2 expression increased in ECs that express ACE2 after infection with the virus, which confirmed that ACE2 is an important target in virus-induced ECs and vascular damage [31] . In addition, David 6 et al. found that the activation and proliferation of mononuclear macrophages and plasma cells in tissue-specific immunopathological responses appear to be associated with the abnormal reticuloendothelial response caused by pulmonary capillaritis; however, the exact mechanism is unclear [32] . These studies suggested that the mechanism of multi-organ damage caused by COVID-19 might be closely related to endothelial dysfunction. ECs have an important role in regulating systemic vascular permeability, tissue barrier, coagulation, and inflammation; therefore, [33, 34] . In addition, pericytes, which specifically express high levels of ACE2, are also potential SARS-CoV-2-infected cells, and have a role in maintaining vascular niche stability and normal endothelial cell function, such that viral destruction and systemic inflammatory states exacerbate pericyte and endothelial cell dysfunction, gradually causing fibrosis in the myocardium and kidney [35, 36] . 7 In addition to causing multi-organ functional impairment, COVID-19 is also a disease with a high incidence of vasculitis and thrombosis [34] . A retrospective analysis of 183 patients with severe novel coronavirus pneumonia (NCP) found that elevated D-dimer and fibrin degradation products (FDP), prolonged prothrombin time (PT), and activated partial thromboplastin time (APTT) were prevalent in patients, and these elevated levels were more pronounced in patients who died [37] . Magro et al. found extensive inflammatory thrombotic vascular lesions in skin and lung tissue in patients with NCP, characterized by respiratory failure and a purpuric rash, which were closely associated with complement pathway activation and an associated procoagulant state [30] . Many recent studies have concluded that endothelial dysfunction is a key factor causing vasculitis and thrombosis, and that the systemic inflammatory syndrome caused by COVID-19 and direct viral invasion of ECs are key factors that exacerbate endothelial dysfunction [33, 34] . These studies demonstrated that COVID-19 patients have severe and extensive structural and functional damage in the vascular niche, which can be triggered by apoptosis caused by direct viral invasion of cells, or by the secondary systemic "inflammatory cytokine storm", activation of the complement system, and vasculitis. This damage further impairs the normal tissue repair function of the vascular niche and aggravates the ischemic and hypoxic damage of organ tissues. Early signs of pulmonary and renal interstitial fibrosis have been shown in some patients with COVID-19; therefore, it is necessary to intervene early to prevent the progression of organ fibrosis caused by chronic damage and to improve the survival rate and quality of life of patients with COVID-19. Further understanding the cellular signaling pathway changes in the vascular niche during organ damage and fibrosis will help investigators to find targeted therapeutic agents. 8 damage Studies have found that ECs produce VEGF, matrix metallopeptidase 2 (MMP-2), and chemokines to promote neovascularization during acute injury in the lung, liver, and kidney [16, 38] . Renal tubular epithelial cells can regulate the angiogenesis function of ECs by upregulating Rab7 gene expression, and mediating the expression of Rab7/MMP-2/VEGF axis [39] . However, when organ damage persists, ECs are aberrantly activated to produce pro-fibrotic mediators such as TGF-β, CCL, and FGF, which induce fibroblast proliferation and production of the ECM [16, 38, [40] [41] [42] . This role of ECs is known as the vascular secretory function, and the secreted cytokines are collectively referred to as vascular secretory factors, which act on both their own and surrounding cells [16, 41] . ET-1 is a potent vasoconstrictor and pro-fibrotic substance produced by ECs, and a study by Wermuth et al. found that ET-1 induces TGF-β receptor 1 and 2 gene expression to promote EndoMT, mediated by TGF-β [43] . Arfian et al. found that after knockout of the endothelin-converting enzyme-1 (ECE1) gene, the level of ET-1 was downregulated and the degree of renal fibrosis was alleviated, which finding provided a theoretical basis for new treatments of fibrotic diseases [44] . EndoMT was first reported in cardiac development and recently it has been found to be a classical change of ECs in the repair of organ damage, which is mainly activated and mediated by the TGF-β/Smads signaling pathway, and by Smad-independent pathways, such as p38 mitogen-activated protein kinase (p38 MAPK)/extracellular signal-related kinase (ERK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathways [45, 46] binds directly binds to the SNAIL gene and increases its promoter activity under TGF-β signaling induction, thereby promoting EndoMT and fibrosis in the heart [48] . In COVID-19, Varga et al. found SARS-CoV-2 viral particles in ECs and infiltration of surrounding inflammatory cells in the heart and kidney of different patients [49] . Many scholars have demonstrated an important role for ECs in regulating inflammatory immune responses and damage repair in organ epithelial cells in patients with COVID-19, and even suggested that EndoMT and epithelial to mesenchymal transition (EMT) may be central to pulmonary fibrosis after COVID-19 [33, 34, 50] . Pericytes not only act as support cells for microvessels, but also are directly involved in the regulation of organ fibrosis by vascular niches [51] . Wang et al. used Notch1 inhibitors in mice with pulmonary fibrosis, which successfully inhibited pericyte proliferation and differentiation, and attenuated pulmonary fibrosis, by inhibiting the Notch1/platelet-derived growth factor receptor β (PDGFRβ) /Rho-associated protein kinase 1 (ROCK1) signaling pathway [52] . The regulatory role of pericytes in organ fibrosis is mainly achieved through the secretion of PDGF, which not only induces fibroblasts to produce ECM, but also stimulates PMT [53] . PDGF-BB upregulates the expression of downstream effectors AKT and ERK, leading to the activation of the PDGF-BB/PI3K/AKT signaling pathway, which effectively promotes the migration and proliferation of pericytes in the liver and heart, ultimately leading to the progression of liver and lung fibrosis [54, 55] (Figure 1 ). In addition, the transcription factor Twist1 in hepatic stellate cells (HSCs, i.e., hepatic vascular niche pericytes) promotes exosome microRNA (miR)-214 and miR-199a-3p contents under TGF-β signaling induction, the activation of HSCs, and fibrosis in the liver [56, 57] . Pericytes express ACE2 and are thus possible targets for SARS-CoV-2 virus infection; however, this has not been proven experimentally [35, 36] . Similar to ECs, pericytes have been shown to convert to myofibroblasts in a variety of organs, and this conversion is known as PMT [20] .In cardiac, pulmonary, and renal fibrosis, TGF-β1 aberrantly activates pericytes, allowing them to develop myofibroblastic properties, such as expressing alpha smooth muscle actin (α-SMA), and it was confirmed using genetic genealogy tracing and RNA sequencing that renal myofibroblasts are mainly derived from pericytes [10, 58, 59] . In addition to TGF-β, Su et al. found that sirtuin 3 (SIRT3) is also a key molecule in the cardiac PMT process: PMT was increased after knockdown of the SIRT3 gene, along with increased formation of reactive oxygen species (ROS) and further myocardial damage [60] . Woodhoo et al. found high expression of an mRNA-binding protein, human antigen R (HUR), in α-SMA-expressing pericytes, and after silencing the HUR gene, the liver damage, inflammation, and oxidative stress were all alleviated [61] . Macrophages and B lymphocytes in the vascular niche have an inflammatory immune role during organ damage and fibrosis [62] . When organs are damaged, M1-type macrophages, with a pro-inflammatory phenotype, are activated, producing pro-inflammatory cytokines, chemokines, and angiogenic factors that promote the phagocytosis of injured cells [63, 64] . As the disease continues to progress, M2-type macrophages, with a pro-fibrotic phenotype, are activated, producing TGF-β1, PDGF-BB, and insulin-like growth factor 1 (IGF-1) to promote cell proliferation and plaque formation [63, 64] (Figure 1 ). The mechanism of activation of M2-type macrophages is currently unknown, although some studies have found that the IL-6/signal transducer and activator of 11 transcription 3 (STAT3) signaling pathway is closely related to it [63, 65] . Immune cells, including macrophages and lymphocytes, are the main effector cells of the systemic inflammatory immune response in patients with COVID-19 [66] . In patients with COVID-19, some investigators found that IL-6 could activate macrophages to release IL-6, and the continuous activation of macrophages and high levels of IL-6 together could exacerbate inflammation and lung epithelial cell damage [66, 67] . Meprin β, a member of the astacin family of metalloproteinases, has catabolic properties and cleaves Triggering receptor expressed on myeloid cells 2 (TREM2) expressed by macrophages, attenuates macrophage phagocytosis, and cleaves the IL-6 receptor (IL-6R) of macrophages, producing new bioactive secreted (s)IL-6R fragments to induce proinflammatory activity in macrophages [68, 69] . In the liver, macrophages have the ability to suppress the expression of the pro-fibrotic phenotype of HSCs while promoting liver regeneration through in situ clearance of dead cells; however, this process is easily inhibited by excessive secretion of pro-fibrotic mediators from vascular niches [70, 71] . Similarly, many studies found that B lymphocytes gradually infiltrate into the kidney, heart, and liver, and produce small amounts of TGF-β1 and inflammatory factors that synergize with macrophages to induce organ fibrosis [72] [73] [74] . Moreover, in the kidney, macrophages are converted to myofibroblasts; however, whether this conversion also exists in other organs, and its significance in the organ fibrogenic process, remains to be determined [21, 75] . MSCs are multifunctional stem cells located around the vascular niche and have a role in regulating the maturation, proliferation, and activation of various immune cells [76] . Researchers labeled MSC-like cells around blood vessels with GLI family zinc finger 1 (Gli1, a marker of mesenchymal cells) and confirmed that MSCs are one of the sources of myofibroblasts in the fibrotic process of several organs [5, 77] . MSCs are characterized mainly by their promotion of tissue healing and inhibition of fibrosis in the repair of organ damage. In addition, the exosomal miR-34c-5p derived from MSCs in the kidney can enter pericytes to modulate multiple pro-fibrotic signaling pathways, such as TGFβ/Smad3 and PDGF-BB/PI3K/ERK, and alter pericyte phenotypes by inhibiting core fucosylation (CF) [78] . Transplanted MSCs also promoted type 2 alveolar cell proliferation, attenuated macrophage infiltration, and inhibited lung fibroblast proliferation [79] . The above studies provide a new direction for antifibrotic therapy. Some investigators found that MSCs and their secreted cytokines (such as IFN-γ, TGFβ, IL-10, and prostaglandin E2 (PGE2). Moreover, exosomes also have immunomodulatory effects in COVID-19, and MSC transplantation was proposed as a new approach for COVID-19 treatment [80] . Myofibroblasts (MyoFs) are the main effector cells in the repair and fibrosis of damage to various organs and are mainly derived from resident fibroblasts, epithelial cells, ECs, pericytes, and MSCs [19] [20] [21] 81] . MyoFs are not only activated by cellular necrosis products, but also are regulated by various cytokines, chemokines, and pro-fibrotic mediators secreted by the vascular niche [19] [20] [21] 81] . Normally, activated MyoFs are inactivated and lysed after the completion of tissue repair; however, when disease and damage continue to stimulate MyoF activation, a large amount of α-SMA, collagen, fibronectin (FN), and other ECM components are produced and deposited continuously in the tissue interstitial space, resulting in progressive tissue stiffness and fibrosis [82] (Figure 1 ). In addition to the TGF-β/Smads signaling pathway in the vascular niche, the classical pro-fibrotic signaling pathways Wnt/β-catenin and Notch/Jagged from epithelial cells also activate fibroblasts [83, 84] . Extensive studies showed that MyoFs have similar roles in skin fibrosis, intestinal fibrosis, spinal 13 cord fibrosis, and Graves' ophthalmopathy, in addition to their roles in the four major organs (heart, kidney, lung, and liver) [85] [86] [87] [88] . In COVID-19, patients with NCP usually suffer from severe lung, heart, and kidney damage, and clinical evidence of organ fibrosis also exists [23, 24, 29] . Tian et al. found fibroblast proliferation in both the lung and heart in autopsies of patients who died from COVID-19, leading to increased myofibroblast content and accumulation of the ECM and fibrin around blood vessels and tissues [89] . To date, only two antifibrotic agents (pirfenidone and andnidanib) have been clinically approved by the United States Food and Drug Administration (FDA) for idiopathic pulmonary fibrosis [90] . Representative targeted anti-liver fibrosis agents, such as obeticholic acid (a Farnesoid-X receptor (FXR) agonist), Aramchol (a stearoyl-CoA desaturase (SCD-1) inhibitor), and Cenicriviroc (a CCR2/5 antagonist), are in phase III trials [91] . Treatments against renal fibrosis currently rely only on blocking the renin-angiotensin-aldosterone system (RAAS) and delaying the progression of fibrosis through the renoprotective effects of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB) [92] . Overall, most of the current therapies can only delay the progression of fibrosis, with no significant improvement in reversing organ fibrosis or improving survival; therefore, the search for specific anti-fibrotic drugs remains a current research hotspot. In addition to drug therapy, stem cell therapy has also been recognized as a therapeutic approach for organ fibrosis. Wu et al. showed that embryonic stem cell-derived MSC-like cell populations (named immunity-and-matrix-regulatory cells (IMRCs)) had better immunomodulatory and anti-fibrotic functions in a mouse model of pulmonary fibrosis, as evidenced by lower levels of pro-inflammatory factor expression, effective inhibition of TGF-β1-induced cellular transdifferentiation, and high levels of MMP1 to degrade the ECM [93] . Many diseases leading to organ fibrosis involve disorders of sugar, protein, and lipid metabolism in damaged organs; therefore, it has been suggested that targeted metabolic regulation, such as targeting glycolytic enzyme (hexokinase, phosphofructokinase (PFK), and pyruvate kinase (PK)) pathways and targeting fatty acid metabolizing enzyme pathways (CD36, free fatty acid receptor 1 (FFA1R, also known as GPR40), and G protein-coupled receptor 84 (GPR84)), could regulate ECM production and metabolism indirectly, and thus is also an approach to treat organ fibrosis [94] . Some scholars have found that the organ fibrosis in TCM collateral disease is very similar to that in the vascular niche. In collateral disease, collaterals are equivalent to the microvessels of organs and their surrounding microenvironment, and the lesions of collaterals lead to the dysfunction of the organs around which they are located, ultimately leading to the occurrence of "Ji Ju" or "Zheng Gan" of organs, i.e., fibrosis-like changes [95] [96] [97] . Many TCM compounds in collateral medicine (such as "DahuangZhechong Pills (DHZC) ", "BuyangHuanwu Decoction (BYHW) ", "QiliQiangxin Capsules (QLQX) ", "ShenSongYangXin Capsule (SSYX)" and "XuefuZhuyu Decoction (XFZY)") and monomers (such as puerarin, mistletoe, and tanshinone IIA) have shown anti-fibrotic properties in experimental studies and clinical applications (Figure 1 ) [98 -101] . Both TCM and Western medicine involve direct intervention for fibrosis to inhibit fibroblast increase and ECM generation by regulating various fibrosis pathways in the vascular niche. Many studies have shown that in rat models of pulmonary fibrosis, the TCM compound BYHW can reduce the levels of connective tissue growth factor (CTGF) and phosphorylated (p)-AKT, which reduced pulmonary fibrosis in rats, and also regulated the PI3K/AKT/ endothelial nitric oxide synthase (eNOS) pathway to improve pulmonary vascular remodeling [102, 103] . In a mouse model of myocardial infarction, BYHW could promote angiogenesis in the infarct border zone, reduce the extent of myocardial infarction, and reduce myocardial fibrosis and inflammation by upregulating the caveolin-1 (Cav1)/VEGF signaling pathway [104] . QLQX could not only upregulate VEGF expression in cardiac ECs, but also upregulated miR-345-3p and inhibited the TGF-β1/Smad3 signaling pathway to inhibit fibroblast activation effectively in a rat model of chronic heart failure (CHF) induced by doxorubicin (DOX) [98, 105] . Both the compounds XFZY and SSYX have a good inhibitory effect on EndoMT and fibroblast activation in the heart, reducing fibrosis and improving cardiac function by inhibiting the TGF-β1/Smad signaling pathway [106, 107] . QishenYiqi Pills (QSYQ) are a renoprotective drug, and some studies have found that QSYQ can protect organs by inhibiting the TGF-β/Smad, PI3K/AKT/mechanistic target of rapamycin (mTOR) and Wnt1/β-catenin signaling pathways in the heart and kidney of mice, significantly reducing the degree of EndoMT in the heart and kidney of rats, and reducing collagen expression and improving heart and kidney microcirculation disorders [99, 101, 108, 109] . YishenHuoxue Recipe (YSHX) can reduce renal fibrosis and mediate renal angiogenesis by inhibiting TGF-β/Smad signaling-mediated EndoMT, but also upregulates the miR-126/VEGF/Notch signaling pathway [110, 111] . In addition to TCM compounds, puerarin, a TCM monomer, could effectively reduce endothelial dysfunction, and protected heart and kidney tissues by inhibiting TGF-β, PI3K, and p38 MAPK signaling, three classic signaling pathways of EndoMT [100, 112, 113] . The TCM monomers astragalus and Paeoniae radix rubra extract can effectively inhibit TGF-β1/Smad2 and 3 signaling pathways and reduce type I and III collagen, fibronectin, and α-SMA levels [114] . Tanshinone IIA was able to reduce inflammation and fibrosis levels, and improve the microvascular microenvironment, by inhibiting TGF-β/Smad and nuclear factor kappa B (NF-κB) signaling pathway activation in a rat model of chronic kidney disease [115] . In addition, Gao et al. used tanshinone IIA in combination with puerarin (tanshinone IIA:puerarin = 1:1 was the most effective), which reduced the expression of TGF-β and regulated the expression of inflammatory pathway-related proteins Toll-like receptor 4 (TLR4) and CCAAT enhancer binding protein beta (C/EBP-β). This not only effectively inhibited myocardial fibrosis and cardiac remodeling, but also reduced cardiac inflammatory response, protected ECs and improved hemodynamics and vascular permeability by regulating macrophage phenotype and inflammatory factor expression [116] . Others have found that salvianolic acid B (SA-B) can downregulate TGF-β/p38 MAPK and TGF-β/Smad to inhibit the activation of hepatic stellate cells, thus representing a potential anti-hepatic fibrosis drug [117, 118] . Previous studies have shown that inflammation and oxidative stress are also important factors in exacerbating organ fibrosis. Some studies have found that LianhuaQingwen Capsules (LHQW) can treat COVID-19 mainly through reducing the production of pro-inflammatory mediators TNF-α and IL-6, controlling the inflammatory storm, and decreasing EndoMT numbers, thereby reducing lung injury [119] . DHZC can effectively inhibit macrophage infiltration into tissues in the hepatic vascular niche, while inhibiting the PI3K/AKT pathway to attenuate abnormal activation of ECs and exert anti-hepatic fibrosis effects [120] . Compound FuzhengHuayu formula (FZHY) can regulate the inflammatory immune response and slow down the speed of liver fibrosis by inhibiting the activation of lymphocytes and hepatic stellate cells [121] . Mistletoe, a TCM monomer, inhibits the infiltration of M1-type macrophages in the renal interstitium, while inhibiting M2-type macrophage activation and reducing inflammation and MMT [122] . Curcumin has been shown to delay renal fibrosis progression in mice by preventing inflammatory factor release and reducing extracellular matrix deposition [123] . Polydatin reduces the renal oxidative stress response and attenuates diabetic renal fibrosis by regulating the Connexin32/NADPH oxidase 4 (Cx32/Nox4 ) signaling pathway [124] . As an extremely contagious disease, COVID-19 has received much attention for its treatment strategies. Current treatment strategies are mainly antiviral therapy, immunosuppressive/anti-inflammatory therapy, and complication treatment [125, 126] . In western medicine, ACE2 receptor blockers are mainly used to prevent the virus from binding to ACE2 on epithelial cells and endothelial cells of the lung and intestine so as to prevent the virus from entering the human body, and traditional antiviral drugs (such as chloroquine, faraciclovir, and rindacivir) can also achieve therapeutic effects by inhibiting viral replication [125, 126] . In addition, due to the severe "cytokine storm" during the progression of COVID-19 disease, immunosuppressive/anti-inflammatory therapy will be more helpful to treat the disease and improve the prognosis. Interferon γ, corticosteroids, tumor necrosis factor blockers, and IL-6 antagonists can effectively reduce the proinflammatory activity of monocytes and macrophages, inhibit the production of inflammatory factors, and regulate the body's immunity, thereby reducing the damage of vascular niches and various tissue cells and preventing complications such as renal failure and pulmonary fibrosis [127, 128] . Stem cell therapy has also shown good immunomodulatory and tissue repair effects in the treatment of COVID-19, and although its side effects remain controversial, it is inevitable that the use of stem cells and their exosomes for the relevant treatment of COVID-19 and fibrosis will also certainly occupy an important place in the future [127, 128] . [135, 136] . Two meta-analyses found that the treatment response rate, chest CT improvement rate, and symptom disappearance rate were higher in the TCM combined with western medicine treatment group than in the western medicine group, and only a small number of adverse events were reported in western medicine [137, 138] . Thus, in order to seek better treatment options, improve organ injury and fibrosis, and improve the prognosis of patients, integrated traditional Chinese and western medicine treatment options are a good choice. From the treatment and research of organ fibrosis and COVID-19, we found that many classical TCM compounds and monomers have multi-level and multi-target therapeutic effects in the process of organ injury and repair, which is more in line with the intervention requirements of inhibiting the pathological process of fibrosis caused by the activation of multiple signaling pathways in the vascular niche. This provides us with a new research direction for identifying more effective drug 19 targets and TCM formulas to delay or even reverse the process of organ fibrosis. Based on current research on the role of the vascular niche in organ fibrosis, as well as organ injury in COVID-19, we found that the role of the vascular niche in organ injury and repair cannot be ignored. On the one hand, the vascular niche can produce cytokines from ECs, pericytes, macrophages, and MSCs, such as TGF-β, PDGF-BB, FGF, ET, and IL, and regulate the inflammatory response and injury repair in organ tissues through MMP-2/VEGF, TGF-β/Smads, p38 MAPK/ERK, PI3K/AKT, and PDGFRβ/ROCK1 signaling pathways. On the other hand, under persistent chronic injury, ECs, pericytes, macrophages, and MSCs in the vascular niche will be abnormally activated, continuously transforming into myofibroblasts. This increases the source of ECM in organ tissues, leading to excessive scar formation at the organ injury site, and affects the normal physiological function of organs. Currently, scholars have developed various anti-fibrotic drugs based on the mechanism by which the vascular niche affects organ fibrosis. According to the study of collateral diseases in TCM, a variety of traditional Chinese medicine compounds and monomers can inhibit the abnormal activation of vascular niche cell signaling pathways in different organs, achieving a significant anti-fibrotic effect. In particular, TCM compounds and monomers in collateral diseases usually play a multi-level and multi-target intervention role in protecting vascular niches and exert anti-fibrotic functions. Thus, further in-depth study of collateral disease-related TCM should be performed to develop more effective strategies to delay or even reverse organ fibrosis and protect against COVID-19 organ injury. None. The vascular niche and its basement membrane Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors Vascular niche contribution to age-associated neural stem cell dysfunction Blood Vessels and Vascular Niches in Bone Development and Physiological Remodeling Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Spectrum of Fibrotic Lung Diseases Key Players of Hepatic Fibrosis Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy Decoding myofibroblast origins in human kidney fibrosis Fibrosis in the central nervous system: from the meninges to the vasculature Quantitating skin fibrosis: innovative strategies and their clinical implications Fibrosis--a lethal component of systemic sclerosis Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases Macrophage-to-Myofibroblast Transition Contributes to Interstitial Fibrosis in Chronic Renal Allograft Injury Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis Dermatologic manifestations and complications of COVID-19 Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses Tissue-specific Immunopathology in Fatal COVID-19 The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection COVID-19 is, in the end, an endothelial disease Atrial fibrillation in COVID-19: A review of possible mechanisms The ACE2 expression in human heart indicates new potential 25 mechanism of heart injury among patients infected with SARS-CoV-2 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia UCP2-induced hypoxia promotes lipid accumulation and tubulointerstitial fibrosis during ischemic kidney injury Hypoxic tubular epithelial cells regulate the angiogenesis of HMEC-1 cells via mediation of Rab7/MMP-2 axis LTBP4 affects renal fibrosis by influencing angiogenesis and altering mitochondrial structure Angiocrine functions of organ-specific endothelial cells Mechanisms of hepatic stellate cell activation Stimulation of Transforming Growth Factor-beta1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1 Endothelin 26 converting enzyme-1 (ECE-1) deletion in association with Endothelin-1 downregulation ameliorates kidney fibrosis in mice TGF-beta/SMAD Pathway and Its Regulation in Hepatic Fibrosis New insights into TGF-beta/Smad signaling in tissue fibrosis Non-coding RNA in endothelial-to-mesenchymal transition Foxm1 is a critical driver of TGF-beta-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter Endothelial cell infection and endotheliitis in COVID-19 Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? The evolving role of renal pericytes Notch1 promotes the pericyte-myofibroblast transition in idiopathic pulmonary fibrosis through the PDGFR/ROCK1 signal 27 pathway PDGF in organ fibrosis Role of PDGFR-β/PI3K/AKT signaling pathway in PDGF-BB induced myocardial fibrosis in rats The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-beta pathway MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities Sirtuin 3 is essential for hypertension-induced cardiac fibrosis via mediating pericyte transition Human antigen R contributes to hepatic stellate cell activation and liver fibrosis The angiocrine Rspondin3 instructs interstitial macrophage transition via metabolic-epigenetic reprogramming and resolves inflammatory injury Macrophages in Tissue Repair, Regeneration, and Fibrosis Macrophages: versatile players in renal inflammation and fibrosis IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Meprin beta cleaves TREM2 and controls its phagocytic activity on macrophages Silencing lncRNA Lfar1 alleviates the classical activation and pyoptosis of macrophage in hepatic fibrosis Liver regeneration and inflammation: from fundamental science to clinical applications Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction Pericardial Adipose Tissue Regulates Granulopoiesis, Fibrosis, and Cardiac Function After Myocardial Infarction The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis Mesenchymal stem cells and immunomodulation: current status and future prospects Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells Bone marrow mesenchymal stem cell-derivedexosomal miR-34c-5p ameliorates RIF by inhibitingthe core fucosylation of multiple proteins Human umbilical cord mesenchymal stromal cells attenuate pulmonary fibrosis via regulatory T cell through interaction with macrophage Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment Myofibroblast in Kidney Fibrosis: Origin, Activation, and Regulation The myofibroblast matrix: implications for tissue repair and fibrosis Tubule-Derived Wnts Are Required for Fibroblast Activation and Kidney Fibrosis Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog Understanding the impact of fibroblast heterogeneity on skin fibrosis Wu-Mei-Wan ameliorates chronic colitis-associated intestinal fibrosis through inhibiting fibroblast activation Laminin alpha5 modulates fibroblast proliferation in epidural fibrosis through the PI3K/AKT/mTOR signaling pathway Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis Antifibrotic Roles of RAAS Blockers: Update Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis Targeting metabolic dysregulation for fibrosis therapy Discussion on pathogenesis and treatment of hepatic fibrosis based on collateral disease theory Pathogenesis and treatment of renal interstitial fibrosis based on collateral disease theory Microdysentery and organ fibrosis Cardio-protecteffect of qiliqiangxin capsule on left ventricular remodeling, dysfunction and apoptosis in heart failure rats after chronic myocardial infarction Effects and mechanisms of QiShenYiQi pills and major ingredients on myocardial microcirculatory disturbance, cardiac injury and fibrosis induced by ischemia-reperfusion Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-beta Signaling Pathway Activation in Type Diabetic Rats Quercetin Inhibits Pulmonary Arterial Endothelial Cell Transdifferentiation Possibly by Akt and Erk1/2 Pathways Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats via Downregulation of Related Protein and Gene Expression Ameliorative Effects and Mechanism of Buyang Huanwu Decoction on Pulmonary Vascular Remodeling: Network and Experimental Analyses Buyang Huanwu Decoction Exerts Cardioprotective Effects through Targeting Angiogenesis via Caveolin-1/VEGF Signaling Pathway in Mice with Acute Myocardial Infarction Qiliqiangxin improves cardiac function and attenuates cardiac remodelling in doxorubicin-induced heart failure rats Ameliorative effects of Xue-Fu-Zhu-Yu decoction, Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-β1/Smad signaling QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway Qishen Yiqi Dripping Pill Protects Against Diabetic Nephropathy by Inhibiting the Wnt/beta-Catenin and Transforming Growth Factor-beta/Smad Signaling Pathways in Rats Yishenhuoxue formula regulates TGF-β/Smad signal transduction to protect rats against Diabetic kidney disease injury Research on the intervention of Yishen Huoxue prescription to renal fibrosis through the signal regulation by microRNA-126 to VEGF-Notch, Zhonghua wei zhong bing ji jiu yi xue Puerarin attenuates the endothelial-mesenchymal transition induced by oxidative stress in human coronary artery endothelial cells through PI3K/AKT pathway Puerarin attenuates renal fibrosis by reducing oxidative stress induced-epithelial cell apoptosis via MAPK signal pathways in vivo and in vitro Astragalus and Paeoniae radix rubra extract inhibits liver fibrosis by modulating the transforming growth factorbeta/Smad pathway in rats Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice Salvianolic Acid B Inhibits Activation of Human Primary Hepatic Stellate Cells Through Downregulation of the Myocyte Enhancer Factor 2 Signaling Pathway Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho-Smad2/3 at linker regions in vivo 36 and in vitro Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic Dahuang Zhechong pill attenuates CCl4-induced rat liver fibrosis via the PI3K-Akt signaling pathway Fuzheng Huayu Capsule Attenuates Hepatic Fibrosis by Inhibiting Activation of Hepatic Stellate Cells Quercetin ameliorates kidney injury and fibrosis by modulating M1/M2 macrophage polarization Recent Advances of Curcumin in the Prevention and Treatment of Renal Fibrosis Polydatin attenuates renal fibrosis in diabetic mice through regulating the Cx32-Nox4 signaling pathway Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 COVID-19: Unmasking Emerging SARS-CoV-2 Variants Therapeutic Strategies The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 Immunomodulation and immunotherapeutics of COVID-19 Understanding COVID-19 in Wuhan From the Perspective of Cold-Dampness: Clinical Evidences and Mechanisms Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming Traditional Chinese Medicine, Qingfei Paidu Decoction and Xuanfei Baidu Decoction, Inhibited Cytokine Production via NF-kappaB Signaling Pathway in Macrophages: Implications for Coronavirus Disease 2019 (COVID-19) Therapy The therapeutic efficacy of Huashi Baidu Formula combined with antiviral drugs in the treatment of COVID-19: A protocol for systematic review and meta-analysis Efficacy and safety of Jinhua Qinggan granules for coronavirus disease 2019 (COVID-19): A protocol of a systematic review and meta-analysis Xuebijing injection in the treatment of COVID-19: a retrospective case-control study Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis Author Contributions: All authors were involved in writing and revising this manuscript.